328.27
전일 마감가:
$355.48
열려 있는:
$351.79
하루 거래량:
1.30M
Relative Volume:
1.56
시가총액:
$23.09B
수익:
$3.22B
순이익/손실:
$542.70M
주가수익비율:
43.88
EPS:
7.4805
순현금흐름:
$458.00M
1주 성능:
-7.75%
1개월 성능:
-2.92%
6개월 성능:
+39.64%
1년 성능:
+18.41%
West Pharmaceutical Services Inc Stock (WST) Company Profile
명칭
West Pharmaceutical Services Inc
전화
(610) 594-2900
주소
530 HERMAN O. WEST DRIVE, EXTON, PA
Compare WST vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services Inc
|
327.99 | 25.03B | 3.22B | 542.70M | 458.00M | 7.4805 |
|
ISRG
Intuitive Surgical Inc
|
337.47 | 118.96B | 11.03B | 3.16B | 2.83B | 8.7254 |
|
BDX
Becton Dickinson Co
|
156.35 | 42.15B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
67.89 | 32.78B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
38.75 | 31.82B | 29.14B | 1.07B | 1.05B | 1.1956 |
|
RMD
Resmed Inc
|
195.30 | 27.83B | 5.54B | 1.52B | 1.74B | 10.37 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-09-15 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-24 | 개시 | Barclays | Equal Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-01-08 | 개시 | Citigroup | Buy |
| 2024-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2024-12-12 | 업그레이드 | UBS | Neutral → Buy |
| 2024-02-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-06-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-04-11 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-11-30 | 개시 | UBS | Neutral |
| 2022-10-28 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-10-14 | 개시 | Stephens | Equal-Weight |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-04-24 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-12-12 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-07-26 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-05-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-04-23 | 개시 | William Blair | Outperform |
| 2018-04-25 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-10-03 | 개시 | Stephens | Equal-Weight |
| 2017-09-15 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-10-28 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-09-21 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2016-03-22 | 개시 | Wells Fargo | Outperform |
| 2010-05-14 | 재확인 | UBS | Neutral |
| 2010-02-23 | 개시 | Jefferies & Co | Buy |
| 2008-12-19 | 개시 | UBS | Neutral |
모두보기
West Pharmaceutical Services Inc 주식(WST)의 최신 뉴스
West Pharmaceutical Services Q2 2026 Earnings: Revenue, Net Income, and Financial Highlights - Minichart
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know - TradingView
Here's Why You Should Add Cencora Stock to Your Portfolio Now - TradingView
West Pharmaceutical beats 2Q26 estimates, raises full-year sales and EPS guidance. - Pluang
West Pharmaceutical Delivers Another BeatBut The Real Story Is The Mix Shift (NYSE:WST) - Seeking Alpha
West Pharmaceutical Services, I (WST) Stock Forecasts - Yahoo Finance
West Pharmaceutical's Long-Term Growth Intact - Morningstar
West Pharmaceutical stock trades steady as recent earnings highlight margin resilience - Ad-hoc-news.de
WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook - TradingView
West Pharmaceutical Services, Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:WST) 2026-07-24 - Seeking Alpha
West Pharmaceutical Services Q2 Earnings Call Highlights - TradingView
West Pharmaceutical Services, Inc. (WPS) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
West Pharmaceutical Services, Inc. (WPS) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
West Pharmaceutical (WST) Receives Strong Outlook Amidst Quarterly Performance - GuruFocus
West Pharmaceutical Services, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
West Pharmaceutical Services Inc 2Q 2026: Revenue $872.3M, EPS $2.15— 10-Q Summary - TradingView
[10-Q] WEST PHARMACEUTICAL SERVICES INC Quarterly Earnings Report - Stock Titan
West Pharma says sterile packaging upgrades fuel demand for high-value plastics - Plastics News
West Pharmaceutical Services Inc (WST) Q2 2026 Earnings Call Highlights: Strong Organic Growth ... - Yahoo Finance
West Pharmaceutical Services Inc (WST) Q2 2026 Earnings Call Hig - GuruFocus
WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growth - TradingView
West Pharmaceutical Services (WST) Reports Strong Q2 2026 Earnin - GuruFocus
West Pharma raises profit forecast on strong demand for injectable drug components - 1470 & 100.3 WMBD
Tranche Update on West Pharmaceutical Services, Inc.'s Equity Buyback Plan announced on February 17, 2026. - marketscreener.com
West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum - Benzinga
West Pharmaceutical Services, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Why is West Pharmaceutical Services stock surging today? - Investing.com
Earnings call transcript: West Pharmaceutical beats Q2 2026 estimates, lifts outlook - Investing.com
West Pharmaceutical (WST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Full Transcript: West Pharmaceutical Servs Q2 2026 Earnings Call - Benzinga
West Pharmaceutical Services Releases Q2 2026 Financial Results - AlphaStreet
Is West Pharmaceutical Services Inc (WST) Undervalued After Q2 E - GuruFocus
West Pharmaceutical Services, I (WST) Q2 FY2026 earnings call transcript - Yahoo Finance
West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars - Yahoo Finance
Form 8-K WEST PHARMACEUTICAL SERV For: Jul 23 - StreetInsider
West Pharmaceutical Services (WST) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
West Pharma stock rises 6% on strong earnings beat and raised guidance - Investing.com Canada
West Pharmaceutical raises FY2026 sales and EPS guidance - scanx.trade
West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components - marketscreener.com
(WST) West Pharmaceutical Services, Inc. Expects Q3 Revenue Range $820.0M$835.0M - marketscreener.com
West Pharmaceutical Services earnings beat by $0.29, revenue topped estimates - Investing.com Canada
(WST) West Pharmaceutical Services Expects Full Year 2026 Adjusted EPS Range $8.85$9.05, vs. FactSet Est of $8.62 - marketscreener.com
(WST) West Pharmaceutical Services, Inc. Expects Q3 Adjusted EPS Range $2.14$2.24 - marketscreener.com
Earnings Flash (WST) West Pharmaceutical Services, Inc. Reports Q2 Revenue $872.3M, vs. FactSet Est of $840.0M - marketscreener.com
(WST) West Pharmaceutical Services Expects Full Year 2026 Net Sales Range $3.35B$3.38B vs. FactSet Est of $3.33B - marketscreener.com
Earnings Flash (WST) West Pharmaceutical Services, Inc. Posts Q2 Adjusted EPS $2.37 per Share, vs. FactSet Est of $2.08 - marketscreener.com
West Pharmaceutical Services Inc (WST) Earnings: FY Adjusted EPS Forecast Raised Following Strong Q2 Results - Smartkarma
West Pharmaceutical: Q2 Earnings Snapshot - Yahoo Finance
Earnings Flash (WST) West Pharmaceutical Services, Inc. Posts Q2 Adjusted EPS $2.37 per Share, Vs. FactSet Est of $2.08 - Moomoo
West Reports Second-Quarter 2026 Results - TradingView
West Pharmaceutical stock holds steady on 2026 earnings context - Ad-hoc-news.de
West Pharmaceutical Services Inc (WST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
West Pharmaceutical Services Inc 주식 (WST) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Favorite Annette F | Sr. VP & Chief HR Officer |
Apr 27 '26 |
Option Exercise |
83.47 |
2,817 |
235,135 |
19,645 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Apr 27 '26 |
Sale |
305.20 |
2,817 |
859,753 |
16,828 |
| Winters Chad | VP, Chief Accounting Officer |
Apr 27 '26 |
Option Exercise |
173.22 |
896 |
155,205 |
2,419 |
| Winters Chad | VP, Chief Accounting Officer |
Apr 27 '26 |
Sale |
300.67 |
896 |
269,399 |
1,523 |
자본화:
|
볼륨(24시간):